REPORT ID 3012

United States Ureter Cancer Drugs Market Report 2017

Publish Date
12-Dec-17
Pages
97
Format
Electronic (PDF)

In this report, the United States Ureter Cancer Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Ureter Cancer Drugs in these regions, from 2012 to 2022 (forecast).

United States Ureter Cancer Drugs market competition by top manufacturers/players, with Ureter Cancer Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Altor BioScience Corp
    Eisai Co Ltd
    Exelixis Inc
    GlaxoSmithKline Plc
    MedImmune LLC
    Merck & Co Inc
    ...

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Durvalumab
    Eribulin Mesylate
    Pembrolizumab
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    In-Patient
    Out-Patient

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Ureter Cancer Drugs Market Report 2017
1 Ureter Cancer Drugs Overview
    1.1 Product Overview and Scope of Ureter Cancer Drugs
    1.2 Classification of Ureter Cancer Drugs by Product Category
        1.2.1 United States Ureter Cancer Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Ureter Cancer Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Durvalumab
        1.2.4 Eribulin Mesylate
        1.2.5 Pembrolizumab
        1.2.6 Others
    1.3 United States Ureter Cancer Drugs Market by Application/End Users
        1.3.1 United States Ureter Cancer Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 In-Patient
        1.3.3 Out-Patient
    1.4 United States Ureter Cancer Drugs Market by Region
        1.4.1 United States Ureter Cancer Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Ureter Cancer Drugs Status and Prospect (2012-2022)
        1.4.3 Southwest Ureter Cancer Drugs Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Ureter Cancer Drugs Status and Prospect (2012-2022)
        1.4.5 New England Ureter Cancer Drugs Status and Prospect (2012-2022)
        1.4.6 The South Ureter Cancer Drugs Status and Prospect (2012-2022)
        1.4.7 The Midwest Ureter Cancer Drugs Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Ureter Cancer Drugs (2012-2022)
        1.5.1 United States Ureter Cancer Drugs Sales and Growth Rate (2012-2022)
        1.5.2 United States Ureter Cancer Drugs Revenue and Growth Rate (2012-2022)

2 United States Ureter Cancer Drugs Market Competition by Players/Suppliers
    2.1 United States Ureter Cancer Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Ureter Cancer Drugs Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Ureter Cancer Drugs Average Price by Players/Suppliers (2012-2017)
    2.4 United States Ureter Cancer Drugs Market Competitive Situation and Trends
        2.4.1 United States Ureter Cancer Drugs Market Concentration Rate
        2.4.2 United States Ureter Cancer Drugs Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Ureter Cancer Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Ureter Cancer Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Ureter Cancer Drugs Sales and Market Share by Region (2012-2017)
    3.2 United States Ureter Cancer Drugs Revenue and Market Share by Region (2012-2017)
    3.3 United States Ureter Cancer Drugs Price by Region (2012-2017)

4 United States Ureter Cancer Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Ureter Cancer Drugs Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Ureter Cancer Drugs Revenue and Market Share by Type (2012-2017)
    4.3 United States Ureter Cancer Drugs Price by Type (2012-2017)
    4.4 United States Ureter Cancer Drugs Sales Growth Rate by Type (2012-2017)

5 United States Ureter Cancer Drugs Sales (Volume) by Application (2012-2017)
    5.1 United States Ureter Cancer Drugs Sales and Market Share by Application (2012-2017)
    5.2 United States Ureter Cancer Drugs Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Ureter Cancer Drugs Players/Suppliers Profiles and Sales Data
    6.1 Altor BioScience Corp
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Ureter Cancer Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Altor BioScience Corp Ureter Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Eisai Co Ltd
        6.2.2 Ureter Cancer Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Eisai Co Ltd Ureter Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Exelixis Inc
        6.3.2 Ureter Cancer Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Exelixis Inc Ureter Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 GlaxoSmithKline Plc
        6.4.2 Ureter Cancer Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 GlaxoSmithKline Plc Ureter Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 MedImmune LLC
        6.5.2 Ureter Cancer Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 MedImmune LLC Ureter Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Merck & Co Inc
        6.6.2 Ureter Cancer Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Merck & Co Inc Ureter Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    ...

7 Ureter Cancer Drugs Manufacturing Cost Analysis
    7.1 Ureter Cancer Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Ureter Cancer Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Ureter Cancer Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Ureter Cancer Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Ureter Cancer Drugs Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Ureter Cancer Drugs Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Ureter Cancer Drugs Sales Volume Forecast by Type (2017-2022)
    11.3 United States Ureter Cancer Drugs Sales Volume Forecast by Application (2017-2022)
    11.4 United States Ureter Cancer Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer